CN112789289A - 包含胰岛素肽和egf(a)肽的双功能化合物 - Google Patents

包含胰岛素肽和egf(a)肽的双功能化合物 Download PDF

Info

Publication number
CN112789289A
CN112789289A CN201980064514.4A CN201980064514A CN112789289A CN 112789289 A CN112789289 A CN 112789289A CN 201980064514 A CN201980064514 A CN 201980064514A CN 112789289 A CN112789289 A CN 112789289A
Authority
CN
China
Prior art keywords
insulin
egf
gaqp
fusion protein
gglu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201980064514.4A
Other languages
English (en)
Chinese (zh)
Inventor
M·W·B·蒙策尔
S·霍斯特鲁普
G·K·波夫尔森
M·诺尔曼
T·B·克杰尔德森
C·U·约林加德
P·马德森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN112789289A publication Critical patent/CN112789289A/zh
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201980064514.4A 2018-10-05 2019-10-04 包含胰岛素肽和egf(a)肽的双功能化合物 Withdrawn CN112789289A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18198892.4 2018-10-05
EP18198892 2018-10-05
PCT/EP2019/076889 WO2020070276A1 (en) 2018-10-05 2019-10-04 Bifunctional compounds comprising insulin peptides and egf(a) peptides

Publications (1)

Publication Number Publication Date
CN112789289A true CN112789289A (zh) 2021-05-11

Family

ID=64017248

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980064514.4A Withdrawn CN112789289A (zh) 2018-10-05 2019-10-04 包含胰岛素肽和egf(a)肽的双功能化合物

Country Status (8)

Country Link
US (1) US11649269B2 (https=)
EP (1) EP3861017A1 (https=)
JP (1) JP7434299B2 (https=)
CN (1) CN112789289A (https=)
AR (1) AR116605A1 (https=)
MA (1) MA53809A (https=)
TW (1) TW202028229A (https=)
WO (1) WO2020070276A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115947822A (zh) * 2022-07-04 2023-04-11 北京惠之衡生物科技有限公司 一种长效酰化胰岛素衍生物及其药物组合物和应用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018107117A1 (en) 2016-12-09 2018-06-14 Akston Biosciences Corporation Insulin-fc fusions and methods of use
KR20210029210A (ko) 2018-06-29 2021-03-15 악스톤 바이오사이언시스 코퍼레이션 초장기 작용 인슐린-fc 융합 단백질 및 사용 방법
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
KR20250142943A (ko) 2019-12-19 2025-09-30 악스톤 바이오사이언시스 코퍼레이션 초-장기 작용 인슐린-fc 융합 단백질 및 사용 방법
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
LT3972987T (lt) 2020-04-10 2023-09-25 Akston Biosciences Corporation Antigenui specifinė imunoterapija, skirta sulietiems covid-19 baltymams ir naudojimo būdai
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
CN114729060B (zh) 2020-09-30 2022-11-25 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
EP4373861A4 (en) 2021-07-23 2025-08-20 Akston Biosciences Corp INSULIN-FC FUSION PROTEINS AND METHODS OF USE FOR TREATING CANCER
EP4323413A4 (en) 2022-03-30 2025-10-15 Beijing Ql Biopharmaceutical Co Ltd LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5721432B2 (ja) 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー／エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
MX2010011499A (es) 2008-04-23 2010-11-12 Amgen Inc Variantes de proproteina neutralizante de convertasa subtilisina kexina de tipo 9 (pcsk9) y sus usos.
GB201005005D0 (en) 2010-03-25 2010-05-12 Angeletti P Ist Richerche Bio New vaccine
WO2012177741A1 (en) 2011-06-20 2012-12-27 Genentech, Inc. Pcsk9-binding polypeptides and methods of use
CA2935285A1 (en) 2014-02-21 2015-08-27 Medimmune, Llc Anti-pcsk9-glp-1 fusions and methods for use
CN104558199B (zh) 2014-09-05 2018-07-06 成都康弘生物科技有限公司 一种治疗高胆固醇血症的融合蛋白制备及其用途
WO2016164762A1 (en) 2015-04-08 2016-10-13 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
ES2908373T3 (es) 2015-08-25 2022-04-28 Novo Nordisk As Nuevos derivados de insulina y los usos médicos de los mismos
SI3402811T1 (sl) 2016-01-13 2022-06-30 Novo Nordisk A/S Analogi EGF(A) z maščobnokislinskimi substituenti

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115947822A (zh) * 2022-07-04 2023-04-11 北京惠之衡生物科技有限公司 一种长效酰化胰岛素衍生物及其药物组合物和应用
CN115947822B (zh) * 2022-07-04 2023-08-18 北京惠之衡生物科技有限公司 一种长效酰化胰岛素衍生物及其药物组合物和应用

Also Published As

Publication number Publication date
JP2022504153A (ja) 2022-01-13
TW202028229A (zh) 2020-08-01
US11649269B2 (en) 2023-05-16
WO2020070276A1 (en) 2020-04-09
US20220009989A1 (en) 2022-01-13
AR116605A1 (es) 2021-05-26
EP3861017A1 (en) 2021-08-11
JP7434299B2 (ja) 2024-02-20
MA53809A (fr) 2022-01-12

Similar Documents

Publication Publication Date Title
CN112789289A (zh) 包含胰岛素肽和egf(a)肽的双功能化合物
CN101868476B (zh) 胰高血糖素样肽-1衍生物及其制药用途
JP6657230B2 (ja) インクレチン−インスリンコンジュゲート
KR102002783B1 (ko) 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용
AU2015349890B2 (en) Insulin receptor partial agonists
US9012398B2 (en) Acylated exendin-4 compounds
KR102417487B1 (ko) 지방산 치환기를 가진 egf(a) 유사체
KR101651703B1 (ko) Ｆｇｆ21 돌연변이체 및 이의 용도
KR20110040760A (ko) 대사 질환 및 비만 치료용 ｇｉｐ-기초된 혼합형 항진제
JP2012530145A (ja) Ｇｉｐ受容体活性グルカゴン化合物
KR20070120112A (ko) 연장형 ｇｌｐ-1 화합물
WO2005077094A9 (en) Pancreatic polypeptide family motifs and polypeptides comprising the same
US7595294B2 (en) Vasoactive intestinal polypeptide pharmaceuticals
EP3307769B1 (en) Protease-resistant lipidated glp-1 analogs
EP2935318A1 (en) Novel glp-1 receptor agonists with cholesterol efflux activity
EP3468987A2 (en) Protease-resistant mono-lipidated peptides
EP4476248A1 (en) Glp-1 and glucagon dual agonist peptides with improved biological stability
CN111164098A (zh) Egf(a)类似物、其制品、制剂和用途
US20070293429A1 (en) Vasoactive Intestinal Polypeptide Compositions
HK1249120B (en) Protease-resistant lipidated glp-1 analogs

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20210511